Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29558089 | 1.00 | HTR6 (0.61) | HTR6HTTMEN1KMT2AALDH1A1 | |
| Ethane SCHEMBL28964521 | 0.89 | HTR6 (0.51) | HTR6HTTMEN1KMT2AALDH1A1 | |
| Ethane SCHEMBL28964519 | 0.88 | HTR6 (0.50) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL8415487 | 0.83 | HTR6 (0.66) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL10433225 | 0.80 | HTR6 (0.58) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL24596834 | 0.79 | HTR6 (0.61) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL649929 | 0.79 | HTR6 (0.61) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL5636978 | 0.79 | HTR6 (0.61) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL9237396 | 0.79 | HTR6 (0.56) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL29723138 | 0.79 | HTR6 (0.56) | HTR6HTTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268421-B1 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-05-06 | — | — | EP | claimed |
| US-12509453-B2 | BRM/BRG1 inhibitors and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-04-21 | — | — | US | disclosed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-02-18 | — | — | US | disclosed |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20070088142-A1 | PERFLUOROVINYL ETHER MONOMER HAVING A SULFONAMIDO GROUP | IKEDA MASANORI | 2007-04-19 | — | — | US | disclosed |
| WO-2004014869-A2 | 5,6-FUSED 3,4-DIHYDROPYRIMIDINE-2-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1268421-A2 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074773-A2 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| US-5922733-A | ADMINISTERING TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY, DEPRESSION, EPILEPSY, OBSESSIVE COMPULSIVE DISORDERS, ANOREXIA, BULIMIA AND ALZHEIMER'S DISEASE | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-07-13 | — | — | US | disclosed |
| EP-0770076-A1 | BENZOCONDENSED FIVE MEMBERED HETEROCYCLE CARBOXAMIDES AS 5HT2B/2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996002537-A1 | BENZOCONDENSED FIVE MEMBERED HETEROCYCLE CARBOXAMIDES AS 5HT2B/2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-02-01 | — | — | WO | disclosed |
| EP-0279263-B1 | INDOLE, BENZOFURAN, BENZOTHIOPHENE CONTAINING LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1993-08-04 | — | — | EP | disclosed |
| US-4873259-A | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1989-10-10 | — | — | US | disclosed |
| EP-0279263-A2 | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509453-B2 | BRM/BRG1 inhibitors and uses thereof | SMARCC1, SMARCC2, SMARCA1 | HTR6 767/4885HTT 1919/4885MEN1 2561/4885 |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | HTR6 2657/4885HTT 708/4885MEN1 4044/4885 |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | AIFM2, FABP7, FASN | HTR6 3873/4885HTT 3973/4885MEN1 2671/4885 |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | HTR6 3415/4885HTT 1660/4885MEN1 3206/4885 |
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | HTR6 2447/4885HTT 234/4885MEN1 1366/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | HTR6 2802/4885HTT 1063/4885MEN1 4365/4885 |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | HTR6 2657/4885HTT 708/4885MEN1 4044/4885 |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | HTR6 2657/4885HTT 708/4885MEN1 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.